Joby could become a leader in electric air mobility through advanced aircraft technology and certification progress, but continuing cash burn, shareholder dilution, and demanding commercialization economics create substantial investment risk.
Sell-rated reports
287 tickers rated SellModerna's expanding mRNA vaccine portfolio and promising cancer immunotherapy pipeline could transform its earnings power, but persistent cash burn and an exceptionally demanding valuation leave little room for execution setbacks.
Oklo offers exposure to rising demand for advanced nuclear electricity, supported by technical progress and substantial cash reserves, but unproven commercial reactor economics, heavy capital spending, and shareholder dilution make the investment highly speculative.
Rigetti's modular superconducting quantum architecture and government-backed research create significant long-term growth potential, but weak commercialization, negative cash flow, dilution and demanding valuation undermine the investment case.
D-Wave's commercial quantum computing platform and expanding contracted backlog offer substantial long-term growth potential, but extreme valuation, widening operating losses, and shareholder dilution undermine the current investment case.
Archer could become a significant aerospace and autonomous defense platform through certification and acquisitions, but heavy cash burn, substantial dilution, and unproven commercial economics threaten long-term per-share value.
VinFast's rapid EV expansion and domestic leadership create significant growth potential, but deeply negative margins, heavy cash burn, and dependence on external funding threaten sustainable shareholder value creation.
Lennar’s land-light model, buybacks, and U.S. housing undersupply offer recovery upside if affordability improves, but collapsing margins and weak orders leave earnings exposed if mortgage rates stay high.
Kodiak's validated biopolymer retina platform could transform the $12B anti-VEGF market, but an imminent cash cliff and going-concern warning favor staying sidelined until recapitalization.
Regencell could unlock a specialized ADHD and autism treatment opportunity through successful TCM commercialization, but unproven clinical efficacy, zero product revenue, rising cash burn, and speculative valuation dominate the investment case.
Li Auto has a fortress balance sheet that secures its survival, but a broken growth engine, shrinking vehicle margins and an inability to defend its family SUV niche against Huawei make the stock a value trap in an oversupplied EV market.